The Thai Phase III HIV Type 1 Vaccine Trial (RV144) Regimen Induces Antibodies That Target Conserved Regions Within the V2 Loop of gp 120

The Thai Phase III clinical trial (RV144) showed modest efficacy in preventing HIV-1 acquisition. Plasma collected from HIV-1-uninfected trial participants completing all injections with AL VAC-HIV (vCP1521) prime and AIDSVAX B/E boost were tested for antibody responses against HIV-1 gp 120 envelope...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	AIDS research and human retroviruses 2012-11, Vol.28 (11), p.1444-1457
Hauptverfasser:	Karasavvas, N, Billings, E, Rao, M, Williams, C, Zolla-Pazner, S, Bailer, R T, Koup, R A, Madnote, S, Arworn, D, Shen, X, Tomaras, G D, Currier, J R, Jiang, M, Magaret, C
Format:	Artikel
Sprache:	eng
Schlagworte:	Amino acid sequence Antibodies Clinical trials Conserved sequence Disease transmission Envelopes Enzyme-linked immunosorbent assay Epitopes Human immunodeficiency virus 1 Retrovirus surface plasmon resonance Vaccination Vaccines valine
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!